Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years of age with a diagnosis of Relapse Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS)~* Currently injecting glatiramer acetate 20 mg/1.0 mL per day subcutaneously (SC) for a minimum of 90 days utilizing the autoject 2 for glass syringe for a minimum of 75% of daily injections~* Willing and able to complete all procedures and evaluations related to the study~* Willing to continue to follow usual injection site preparation and routine adjunctive local injection site reactions (LISR) management techniques~* Willing and able to provide written informed consent~Exclusion Criteria:~* Currently using or treated with another immunomodulating therapy (IMT) in conjunction with GA in the 30 days prior to screening for this study~* Currently using an investigational drug or using treatment with any other investigational agent in the 30 days prior to screening for this study~* Pregnant or planning pregnancy or breastfeeding~* Use of any other parenteral medications (e.g., intramuscular, SC, intravenous, etc.) either currently or in the past 30 days prior to screening for this study~* Any other medical or psychiatric conditions that would make the patient unsuitable for this research, as determined by the Investigator~* Unwilling to perform all daily injections with an autoject 2 device~* Previous participation in any study evaluating the new 20 mg/0.5 mL formulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 20 mg/0.5 mL Glatiramer Acetate (Type: ACTIVE_COMPARATOR): Participants received once daily subcutaneous administration of 20 mg glatiramer acetate as 20 mg/1.0 mL utilizing autoject 2 for glass syringe for two weeks (Period 1), followed by 20 mg/0.5 mL utilizing the autoject 2 device for four weeks (Period 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).